Long-term effects of tetrabenazine in hyperkinetic movement disorders

  title={Long-term effects of tetrabenazine in hyperkinetic movement disorders},
  author={Joseph Jankovic and Jennifer C. Beach},
  pages={358 - 362}
Article abstract-Over the past 15 years we have treated 526 patients with severe hyperkinetic movement disorders with tetrabenazine (TBZ), a monoamine-depleting and a dopamine-receptor-blocking drug. We report here the results in 400 patients with adequate follow-up. The response was rated on a scale of 1 to 5 (1 = marked improvement, 4 = no response, 5 = worsening) and was assessed initially and at the last clinic visit. The average duration of TBZ treatment was 28.9 months (+/- 31.1; range, 0… 

Tables from this paper

Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
Comparison of log‐likelihood ratios revealed that age was a reliable predictor of Parkinsonism (P < 0.0001) and TBZ is a safe and effective drug for the long‐term treatment of hyperkinetic movement disorders.
Tetrabenazine Treatment in Movement Disorders
It is concluded that TBZ is a moderately effective treatment of a large variety of hyperkinetic movement disorders, with excellent effects in a subgroup with chorea and facial dystonia/dyskinesias.
Tetrabenazine in the treatment of Tourette syndrome
In this retrospective, open-label study, tetrabenazine was found to be generally safe and well-tolerated in patients with TS.
Tetrabenazine Treatment for Huntington's Disease-Associated Chorea
TBZ was well tolerated and resulted in a significant improvement in modified AIMS scores in HD patients, which support the use of TBZ for chorea in patients with HD.
Short‐term effects of tetrabenazine on chorea associated with Huntington's disease
During short‐term follow-up after a single dose of tetrabenazine, TBZ improves chorea for approximately 5 hours, and this effect is similar to that of a double dose.
Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study
TBZ proved an effective and relatively well tolerated treatment in hyperkinetic disorders, with excellent results in HD, and was more common in OM dyskinesia, which may be related to higher age at TBZ initiation.
The Long-term Effect of Tetrabenazine in the Management of Huntington Disease
Tetrabenazine was well tolerated and produced long-term improvement of motor symptoms in Huntington disease patients, although a slight reduction of benefit occurred during the course of treatment.
Deutetrabenazine in Tics Associated with Tourette Syndrome
The results of this open-label 8-week study suggest that deutetrabenazine is safe and associated with improvement in tic severity in adolescents with TS and troublesome tics.
Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol.
Tetrabenazine was well tolerated and resulted in significant improvements in AIMS scores for patients with refractory tardive dyskinesia, particularly on the motor subset of the modified Abnormal Involuntary Movement Scale.
Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
  • D. Guay
  • Medicine, Psychology
    The American journal of geriatric pharmacotherapy
  • 2010


Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias
Tetrabenazine is an effective and relatively safe drug for a variety of hyperkinetic movement disorders, and the choreatic movement disorders are most amenable to tetrABenazine therapy, but tardive and idiopathic dystonia may also be responsive.
Treatment of hyperkinetic movement disorders with tetrabenazine: A double‐blind crossover study
Tetrabenazine is a useful and safe therapeutic agent in some patients with hyperkinetic movement disorders and shows marked improvement in one patient with Huntington disease and two patients with congenital choreoathetosis.
Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome
Tetrabenazine (which has both presynaptic monoaminedepleting effects and postsynaptic blocking action) was evaluated in nine patients and side effects included drowsiness, “nervousness”, depression, parkinsonism, and oculogyric crises in one, but all undesirable effects cleared with maintenance or reduction of the dosage.
[Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements].
The later drug could be an alternative therapy for those patients in whom TBZ provides unsatisfactory control of the choreatic movements, but it might be the drug of choice in cases with associated depressive illness or organic psychosis.
Treatment of involuntary movement disorders with tetrabenazine
Drowsiness, insomnia, and depression were the most conspicuous unwanted effects, and these may limit the clinical usefulness of the drug.
Tardive stereotypy and other movement disorders in tardive dyskinesias
It is concluded that stereotypy can be readily differentiated from other hyperkinetic movement disorders and that its presence in an adult is highly suggestive of prior exposure to DRBD.
Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.
Haloperidol produced a statistically significant reduction in the frequency of oral dyskinesia, though the effect was most striking during the first two weeks; reversible extrapyramidal symptoms appeared to be negatively correlated with oral dysKinesia.
Tardive akathisia: An analysis of clinical features and response to open therapeutic trials
Tardive akathisia is a particularly disabling form of tardive dyskinesia, frequently persistent for years and often resistant to therapy.
Alpha methylparatyrosine and tetrabenazine in movement disorders.
Although a small number of patients did improve, and short- and long-term remissions occurred in a few, most patients with dystonia were not benefited by either drug.
Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders.
Observations in 15 patients with various hyperkinetic disorders treated with tetrabenazine in doses up to 200 mgm.